# Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

> **NCT04677595** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT04677595
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-17
- **Primary completion:** 2023-10-12
- **Final completion:** 2025-05-22
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677595, "Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04677595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*